Alligator publishes supplementary prospectus
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience publishes Annual Report for 2023
Lund, Sweden, March 21, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2023, as ...
The subscription period in Alligator Bioscience’s rights issue begins today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
Today, on 14 March 2024, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows ...
Notice of extraordinary general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator carries out a rights issue of units of approximately SEK 150.9 million with an over-allotment issue of up to an additional approximately SEK 100.0 million and raises bridge loans
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience AB reports full year financial results for 2023 and for Q4 2023 and provides a business update
Mitazalimab meets OPTIMIZE-1 Phase 2 primary endpoint, demonstrating 40.4% Overall Response Rate and median Overall Survival of 14.3 months ...
Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation
Expected annual cash savings of SEK 20 million Restructuring follows successful conclusion of resource intensive OPTIMIZE-1 Phase 2 trial Fo ...